Related Experiment Video

Updated: Sep 16, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.3K

Advancements in Cutaneous T-Cell Lymphoma Treatment: Unveiling Novel Therapeutic Avenues and Clinical Implications

Zaheer Qureshi1, Abdur Jamil2, Fatima Hameed3

  • 1Department of Internal Medicine, School of Medicine at Quinnipiac University, Bridgeport, CT.

American Journal of Clinical Oncology
|July 10, 2025
PubMed
Abstract

Insights

New immunotherapies and targeted medicines offer hope for advanced cutaneous T-cell lymphoma (CTCL). Research highlights promising treatments like mogamulizumab and brentuximab vedotin, improving outcomes for CTCL patients.

Area of Science:

  • Oncology
  • Dermatology
  • Immunology

Background:

  • Cutaneous T-cell lymphomas (CTCLs) are rare, aggressive non-Hodgkin lymphomas primarily affecting the skin.
  • Advanced-stage CTCL has a poor prognosis with limited therapeutic options.

Purpose of the Study:

  • To review emerging immunotherapies, targeted medicines, combination treatments, and epigenetic modifiers for advanced CTCL.
  • To summarize the current landscape of care for CTCL.

Main Methods:

  • A narrative review of literature identified through searches of PubMed, Science Direct, and Cochrane databases.
  • Articles reporting novel treatments for CTCL were selected and categorized.

Main Results:

  • Promising agents include mogamulizumab (anti-CCR4), brentuximab vedotin (anti-CD30), checkpoint inhibitors (pembrolizumab, durvalumab), and novel agents targeting CD47, IL-2/9/15, and KIR3DL2.
  • Extracorporeal photopheresis with mogamulizumab shows efficacy with a good safety profile.
  • Early clinical trials report positive results, but further research is needed.

Conclusions:

  • Innovative therapies show potential to improve outcomes for advanced CTCL.
  • Ongoing research and personalized treatment strategies are crucial for managing CTCL.
Keywords:
cutaneous T-cell lymphomadermatologicaldisease managementimmunotherapyoncologytherapeutic strategies

More Related Videos

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.5K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.5K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
665
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
517
Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
4.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
2.4K